logo

Did Nevada limit hospitals to only using Remdesivir to treat COVID-19?

By Todd Butterworth
NO

In its July 2020 guidance for responding to the COVID-19 pandemic, the Nevada Department of Health and Human Services deferred to federal treatment recommendations and guidelines, which were evolving based on clinical evidence. Nevada's DHHS itself made no specific treatment recommendations.

The department noted that no FDA-approved drugs had demonstrated safety and effectiveness in randomized controlled trials, but that the FDA granted emergency authorization for Remdesivir to treat severe cases.

In October 2020, the FDA granted full approval of Remdesivir for treating severe COVID-19, and in January 2022, to treat non-hospitalized patients. The drug showed an 87% reduction in the risk of hospitalization in non-hospitalized patients given a three-day course.

Following clinical trials, the National Institutes of Health has expanded treatment recommendations to include a variety of medicines and therapies and Nevada's DHHS continues to recommend following federal guidelines. 

This fact brief is responsive to conversations such as this one.
ABOUT THE CONTRIBUTOR
The Nevada Independent is a nonpartisan, nonprofit news and opinion website founded in 2017 by veteran political journalist and commentator Jon Ralston. The site and its supporting channels are focused on ethical, unbiased and transparent journalism. In general, we aim to gather and disseminate important public information and increase civic engagement. We are supported by corporate donations, memberships, event ticket sales and sponsorships and foundation grants. We disclose all our members and donors. Donors have no influence over our content, ever. The Nevada Independent is the dba for Nevada News Bureau, Inc., a 501(c)3 nonprofit founded in 2010 by Elizabeth Thompson, who now serves as one of The Nevada Independent's managing directors and its Editor.
FACT BRIEF BY
facebook
twitter
email
email